Savi Quetiapine 100 drugs treat schizophrenia (3 blisters x 10 tablets)
Dosage form Box of 3 blisters x 10 tablets
Specifications Quetiapina
Ingredient
| Composition information | Content |
| Quetiapina | 100mg |
Uses
Indications
Savi Quetiapine 100 is indicated in the following cases:
Treatment schizophrenia .
Treatment of bipolar disorder:
quetiapin is active through anti -psychotic trials such as Conditailed Avoidance.
Quetiapin also reverses the impact of homogeneous substances with dopamine, evaluated by behavior or physiological and increases the concentration of dopamine metabolites, the nerve chemical index of Dopamine receptor inhibitors D2.
In preclinical trials forecasting the possibility of foreign symptoms (EPS: Extrapyramidal Symptoms), Quetiapin is not like typical anti -psychotic drugs and has no typical characteristics.
Quetiapin does not cause hypersensitivity to Dopamine D2 receptor when used for long term. Quetiapin only causes weak impact (catalepsy) in the doses of Dopamine D2 receptors. Quetiapin proves the selection on the edge of the brain through the reducing inhibition effect of dopamine neurons in the middle edge of the brain but does not impact on nigrostriatal neurons after long -term use. Immediately after taking the drug and in the long run, Quetiapin can cause muscle disorders very small on the cebus monkeys sensitive to Haloperidol or not.
Mechanism of action:
Quetiapin is an aligned anti -psychotic drug. Quetiapin and metabolites are active in human plasma, Norquetiapin has the effects on many types of neurotransmitter receptors. Quetiapin and Norquetiapin have a work of serotonin receptors (5HT2) in the brain and with Dopamine D1 and D2 receptors. It is the selection with the higher Serotonin receptor (5HT2) in the brain with the Dopamine D2 receptor that is believed to contribute to the anti -psychotic properties on the sieve and the risk of unwanted effects on Quetiapin's pagoda system. In addition, Norquetiapin has high affinity with norepinephrin transportation. Quetiapin and Norquetiapin also have high affinity with histaminergic receptors and adrenergic alpha1, with lower affinity with adrenergic alpha2 and serotonin 5HT1A. Quetiapin has negligible affinity for the Cholinergic Muscarinic or Benzodiazepin receptors.
pharmacokinetics
Adults
The activity of Quetiapin Fumarat is mainly due to the original compound. Quetiapin's multi -dose pharmacokinetics are linearly in the clinical dose proposed and accumulated Quetiapin is predicted when used many times. Quetiapin elimination is mainly through the liver metabolism with an average selling time of about 6 hours during the proposed clinical dose. The concentration in a stable state is expected to be achieved within 2 days of medication. Quetiapin does not interfere with the metabolism of the drug metabolized by the cytochrom P450 enzyme.Children and teenagers
Dynamic data in 9 children from 10 to 12 years old and 12 teenagers have stable treatment with 400 mg of quetiapin twice a day. In a stable state, Quetiapin plasma concentration in children and teenagers (10-17 years old) is similar in adults, although in children taller than adults. AUC (Area Under the Curve) and CMAX of metabolites with Norquetiapin activity is about 62% and 49% higher than children (10 - 12 years old), 28% and 14% respectively in teenagers (13 - 17 years old) compared to adults.
absorption
Quetiapin fumarat is quickly absorbed after drinking, reaching a plasma peak concentration after 1.5 hours.
The bioavailability of Quetiapin is slightly affected when taken with food, whereby the value of CMAX and AUC increases 25% and 15% respectively.
Distribution
Quetiapin is widely distributed throughout the body with an integral distribution of 10 ± 4 liters/kg. 83% of drugs are associated with plasma proteins at the concentration of treatment. In vitro test shows that Quetiapin does not affect the links of Warfarin or Diazepam with human serum albumin. In contrast, Warfarin or Diazepam also does not change the links of Quetiapin.
Metabolism and elimination
After taking the only dose with 14C - Quetiapin radioactive, less than 1% of the dose is eliminated in a constant form, showing that Quetiapin is very strongly metabolized. About 73% and 20% of the dose is recovered in urine and corresponding fertilizers.
quetiapin is metabolized in the liver. The main metabolic paths are sulfoxid chemicals with sulfoxid metabolites and oxidation of parent acid metabolites; Both of these metabolites are not active.
In Vitro studies using human liver microsome shows that CYP3A4 has been involved mainly in the metabolism of quetiapin via cytochrome P450 intermediaries and Norquetiapin metabolites have the main activity formed and eliminated via CYP3A4.
Before taking Savi Quetiapine 100 drugs treat schizophrenia (3 blisters x 10 tablets)
How to use
Savi Quetiapine medicine is used orally, orally during or outside meals.
Dosage
The dosage of drug used is calculated according to quetiapin.
Each 115.14 mg quetiapin fumarat is equivalent to 100 mg of quetiapin.
Adults
schizophrenia treatment:
quetiapin should drink 2 times/day. The total daily dose in the first 4 days of treatment respectively is 50 mg (day 1), 100 mg (dated 2), 200 mg (dated 3), 300 mg (dated 4). From the 4th day onwards, the dose should be adjusted to the dose effectively, usually from 300 - 450 mg/day. Depending on the clinical response and tolerance of each patient, the dose can be adjusted in the range of 150 - 750 mg/day.
Treatment of average to severe revolutionary attacks related to bipolar disorders:
quetiapin should drink 2 times/day. The total daily dose in the first 4 days of treatment respectively is 100 mg (day 1), 200 mg (dated 2), 300 mg (dated 3), 400 mg (dated 4). Increase the dose, reaching 800 mg/day on the 6th day, not more than 200 mg/day. Depending on the clinical response and tolerance of each patient, the dose can be adjusted in the range of 200 - 800 mg/day. Effective doses are usually about 400 - 800 mg/day.
Treatment of depression related to bipolar disorders:
quetiapin should drink 1 time/day before going to bed. The total daily dose in the first 4 days of treatment respectively is 50 mg (day 1), 100 mg (dated 2), 200 mg (dated 3), 300 mg (dated 4). The recommended daily dose is 300 mg. The larger dose of more than 300 mg should be started by experienced doctors in the treatment of bipolar disorder. In each case, clinical trials show that the dose can be reduced to 200 mg.
Room recurrence of emotional or depression in bipolar disorder patients:
In order to prevent relapse of emotional, depression or mixture in bipolar disorders, the patient has responded to treatment with Quetiapin in the treatment of acute bipolar disorders, so they continue to treat with the same dose. The dose may be adjusted depending on the clinical response and tolerance of each patient, in the range of 300 - 800 mg/day, 2 times/day. The lowest dose is effective used for maintenance treatment.
Elderly
Like other anti -psychotic drugs, should be cautious when using Quetiapin in the elderly, especially in the starting stage of using the drug. The frequency of adjusting the dose may need to be reduced and the daily dose is lower than young people, depending on the clinical response and tolerance of each patient. The clearance of Quetiapin in the elderly decreased by 30-50% compared to young people.
The effectiveness and safety of Quetiapin has not been evaluated in depression patients related to bipolar disorder over 65 years old.children and teenagers
Quetiapin is not recommended for children and teenagers under 18 years old.
kidney failure
No dose adjustment in kidney failure.
liver failure
quetiapin metabolizes in the liver. Therefore, caution should be used when using quetiapin in patients with liver failure, especially in the first stage of treatment. Patients with liver failure should start treatment at a dose of 25 mg/day. Dosage should be increased daily about 25 - 50 mg days until the dose is effective, depending on the clinical response and tolerance of each patient.
Note:
What to do when overdose?
Symptoms
In general, signs and symptoms are due to an increase in pharmacological impact of the drug, such as vaginal and sedative, tachycardia, hypotension and acetylcholine resistance.
Overdose can lead to extension of QT, convulsions, epilepsy, pattern, respiratory failure, urinary retention, confusion, delusion and/or agitation, coma and death. Patients with previous severe cardiovascular disease may increase the risk of overdose.
How to handle
There is no specific detoxification for Quetiapin. In case of severe poisoning, it is necessary to consider the ability of many drugs, taking special care measures, including establishment and maintenance of airway, ensuring ventilation and adequate oxygen supply, monitoring and cardiovascular support.
Based on the published document, patients with paranoid symptoms, agitation and acetylcholine resistance syndrome are clearly treated with physostigmin, 1 - 2 mg (continuous electrocardiogram tracking). This is not a standard treatment recommendation because of the potential negative effects of Physostigmin on the heart. Physostigmin can be used without that electrocardiogram (ECG: ElectrocardRam). Do not use physostigmin in case of arrhythmia (any level) or qRS widening.
Research on reducing quetiapin absorption in the overdose has not been conducted. In case of severe poisoning, the stomach may be done within an hour after overdose. Activated carbon can be used to reduce the absorption of Quetiapin.
In case of quetiapin overdose, hypotension should be treated with appropriate measures such as intravenous and/or sympathetic drugs. Epinephrin and dopamine should be avoided because Beta stimulates can lower blood pressure.
Need to continue monitoring and monitoring patients closely until complete recovery.
What to do when you forget 1 dose? If it is close to the next dose, skip the forgotten dose and take the next dose as the usual calendar. Do not take double the dose to compensate for the dose to forget to drink (or consult a doctor or pharmacist).
Side Effects
When using Savi Quetiapine 100 , you may experience unwanted effects (ADR).
Sleep, dizziness, dry mouth , mild weakness, constipation, tachycardia, vertical and indigestion.
Fainting, malignant syndrome caused by sedation, leukopenia, neutropenia and peripheral edema may occur.
Very common, ADR ≥ 10/100
Nervous dysfunction: dizziness, dizziness (1.5), drowsiness (2).
Common, ADR> 1/100
Disorders of blood system and lymph: leukopenia.
Vascular dysfunction: Anti -blood pressure (1.5). Disorders of the digestive system: dry mouth, constipation, indigestion. Neutral leukopenia (7). Uncommon, 1/1000 Rare, ADR Very rare, ADR Note: (1) See the "caution when taking the drug". (2) Sleep may occur, usually in the first 2 weeks and disappear when continuing treatment with Quetiapin. (3) mainly occurs during the weeks to start treatment with the drug. (4) Incrixed serum transaminase symptoms (ALT, AST) or gamma - GT increased in some patients using Quetiapin. These increase often recover when continuing treatment with quetiapine. (5) As well as alpha1-adrenergic inhibitors, quetiapin can cause vertical hypotension, accompanied by dizziness, tachycardia and fainting in some patients, especially in the first stage of dose adjustment. Symptoms of foreign tower Clinical clinical studies in adult patients show that Quetiapin is associated with an increase in the incidence of foreign symptoms compared to the placebo group in patients treating severe depression in bipolar disorders. Using Quetiapin causes an Akathisia, which is characterized by restlessness, subjective insecurity and must move regularly to sit or stand still. This may occur in the first few weeks of treatment. In patients with this symptom, increased dose can be harmful. Late movement disorders If the signs and symptoms of late movement disorders appear, the dose reduction or quetiapine stops. Symptoms of late movement disorders may be severe or appear after stopping treatment. Sleep and dizziness Like sedatives, treatment with quetiapin can cause drowsiness and related symptoms. In clinical trials, the treatment of bipolar depression, onset usually within the first three days of treatment, patched primarily from mild to average. Patients with severe intensity must be re -examined more often, at least 2 weeks from the beginning of drowsiness or until symptoms improve. Patients with severe intensity may have to stop treatment. posture hypotension quetiapin can cause vertical and dizziness. Hypotension posture usually starts at the starting dose and the dose adjustment stage. This may increase the risk of injury due to an accident (fall), especially in the elderly. Therefore, patients should be cautious until they are familiar with the unwanted effects of the drug. Be cautious when using quetiapin in patients with cardiovascular disease, cerebrovascular disease or other pathological conditions that can cause hypotension. If hypotension occurs, it is advisable to consider reducing the dose or increasing the dose slowly, especially in patients with cardiovascular disease. Sleep apnea syndrome Sleep apnea syndrome has been reported in patients using Quetiapin. In patients who use simultaneously with antidepressants and people with a history or a risk of sleep apnea, such as overweight/obesity or men, Quetiapin should be used carefully. epilepsy In control clinical trials, there is no difference in the rate of convulsions in patients treated with quetiapin or placebo. There is no data on convulsions in patients with a history of convulsions. Like other anti -psychotic drugs, it is necessary to be cautious when using Quetiapin to treat patients with a history of convulsions. Evil syndrome caused by sedatives. Malignant syndrome caused by neuroleptic is related to the treatment of anti -psychotic drugs, including Quetiapin. Clinical manifestations include overcrowding, mental changes, muscle spasms, unstable nervous systems and increased creatin phosphokinase. In this case, Quetiapin should be discontinued and appropriate treatment. Neutral leukemia and grain leukemia Heavy neutropenia ( Neutral leukemia should be considered in infections or fever patients, especially in the absence of clear causes and must be clinically monitored. Patients should be advised to report as soon as the signs/symptoms are related to granulocytes or infections (for example, fever, weakness, indifference, or sore throat) at any time during treatment with Quetiapin. Acetylcholin resistance effect Norquetiapin, a metabolic substance of Quetiapin, has a strong average affinity with many types of Muscarinic receptors. This contributes to acetylcholin resistance when quetiapin is used in the recommended dose, when used simultaneously with other drugs with anti -acetylcholine and in case of overdose. Use Quetiapin cautiously in patients taking anti -acetylcholine drugs (Muscarinic). Quetiapin should be used cautiously in patients with current diagnosis or history of urinary retention, prostate hypertrophy with clinical significance, intestinal obstruction or related diseases, glaucoma or closed angle glaucoma. Drug interaction Simultaneous use of Quetiapin with strong liver enzyme drugs such as carbamazepine or phenytoin reduces the plasma concentration of quetiapin. This may affect Quetiapin's treatment effect. Patients who are taking liver enzyme drugs, only starting to treat Quetiapin when Quetiapine's treatment benefits are higher than the risk of liver enzyme stopping. The important thing is that any liver enzyme changes should be changed slowly, if necessary, it can be replaced with liver enzyme non -touch drugs (such as sodium valproat). weight Weight gain has been reported in patients treated with quetiapin and should be monitored with sieve as under the instructions for using anti -psychotic drugs. Hyperglycemia Hyperglycemia and/or hyperglycemia or more severe diabetes that sometimes combine with kemin acid or coma are rarely occurring, including death. In some cases, previous weight gain has been reported, this may be a cause. Clinical monitoring should be monitored according to the instructions for using anti -psychotic drugs. Patients using any anti -brain psychotic drugs include Quetiapin should monitor signs and symptoms of hyperglycemia (such as drinking, urinating, eating a lot and fatigue) and patients with diabetes or having a risk factor for diabetes should monitor blood sugar regularly. Should monitor regular weight. lipid Increased triglycerides, LDL (Low Density Lipoprotein) and total cholesterol and HDL reduction (High Density Lipoprotein) cholesterol have been observed in clinical trials with quetiapin. Lipid changes should be clinically monitored. extends the range of qt In clinical studies and use of Spc (Statistical Process Control) statistical control, Quetiapin has no unwanted effect to extend QT. During the use of the drug, the Quetiapin report extends the QT range at the treatment dose and in case of overdose. Like other anti -psychotic drugs, using caution quetiapin in patients with cardiovascular disease or family history has a QT range. In addition, it is necessary to be cautious when using Quetiapine simultaneously with drugs that extend the QT or sedative, especially in the elderly, patients with congenital QT syndrome, congenital heart failure, heart hypertrophy, hypotension or hypoglycemia. Myocarditis and myocarditis Myocarditis and myocarditis have been reported. However, the causal relationship with Quetiapin has not been studied. Treatment with Quetiapin should be reviewed in patients suspected of myocardial or myocarditis. Stop using drugs Symptoms of acute cessation such as insomnia, nausea, headache, diarrhea, vomiting, dizziness and discomfort have been described after stopping the Quetiapin suddenly. Quetiapine should be stopped gradually for at least 1 -2 week. Elderly patients with mental disorders. Quetiapin is not indicated to treat intellectual dementia related to mental disorders. Random fatal control tests in patients who lose their memory with some typical anti -psychotic drugs show the risk of unexpected effects of brain vascular complications increasing 3 times. The mechanism increases this risk unknown. This increased risk is not excluded in other anti -psychotic drugs or other patients. Should be cautious when using quetiapin in leisure diseases with risk factors for stroke . A study on non -typical anti -psychotic drugs shows that elderly patients who have dementia in mental disorders are at higher risk of death compared to the placebo group. In the two place to control the fugitive for 10 weeks with Quetiapin, there is the same group of patients (n = 710; age: 56 - 99 years old, an average of 83 years old), the mortality rate in patients treated with Quetiapin is 5.5% compared to 3.2% in the placebo group. Difficult to swallow Difficult to swallow has been reported to Quetiapin. Use cautious quetiapin in patients at risk of inhaling pneumonia. Constipation and intestinal obstruction constipation is a risk factor for bowel obstruction. Constipation and intestinal obstruction have been reported to Quetiapin, including death reports in patients at high risk of intestinal obstruction, users simultaneously reducing intestinal peristalsis and/or may not report constipation symptoms. Patients with intestinal obstruction /intestinal obstruction must be closely monitored and special medical care. (6) Anaphylactic reaction was put into reports after the drug was brought to the market. (7) In all clinical trials that are controlled with a placebo on patients with leukemia at the beginning of testing ≥ 1.5 x 109/l, the frequency occurs at least once a neutral leukemia test 1.5 x 109/l, the frequency occurs at least 1 neutral leukemia test (8) Blood glucose at ≥ 126 mg/dl or blood glucose at any time ≥ 200 mg/dl occurs at least one test. Instructions on how to handle ADR If serious ADR occurs, stop taking medication and apply appropriate treatments.
Warnings
Before using the drug you need to read the instructions carefully and refer to the information below.
Contraindicated
Savi Quetiapine 100 contraindicated in the following cases:
Precautions when using
Children
Quetiapin is not recommended for children and teenagers under 18 years of age due to lack of data of drugs in this age group. Clinical trials show that some unwanted effects have a higher frequency in children and adolescents in adults (increasing appetite, high serum prolactin, vomiting, rhinitis, fainting) or may have different effects in children and adolescents (symptoms of foreign tower, irritability) and hypertension. The effects on the thyroid function also observed.
Moreover, the safety in long -term treatment with quetiapin has not been studied for more than 26 weeks.In clinical trials in children and teenagers treat schizophrenia, bipolar and bipolar depression, the research results show that the towering symptoms increased in the group of patients treated with quetiapine compared to the groupbo group.
suicide/intend to commit suicide
Depression is associated with an increase in the risk of suicide, self -destruction and suicide (suicidal events). This risk lasts until the disease is significantly reduced. Because the improvement of the disease may not appear in the first few weeks of treatment or longer, the patient should be closely monitored until the disease is significantly improved. Clinical experience shows that the risk of suicide may increase in the early stages of the recovery process.
In addition, the doctor should consider the potential risk of suicide when stopping sudden treatment with Quetiapin.
Patients with a history of suicide, or suicide thought before treatment may be at risk of suicide and highly suicidal thoughts and need to be closely monitored during treatment. Clinical research with placebo -controlled control of antidepressants in adult patients with mental disorders shows that in the treatment group with antidepressants, there is an increase in the risk of suicide in patients under 25 years older than the group using Placebo.
Monitoring patients, especially those at high risk of suicide, should be performed along with drug treatment, especially in the early stages of the treatment process and when changing the dose. Patients (and patient care) should be warned of the need to monitor the deterioration, suicide behavior or abnormal changes in thinking and behavior. Find medical advice immediately if the symptoms appear.
Clinical studies in depression patients related to bipolar disorders show the risk of suicide in 25 -year -old patients who have been treated with quetiapin increased compared to those who treated with Placebo (equivalent to 3.0% compared to 0%).
Metabolism
Clinical studies show that the metabolism changes in the direction of worsening, including changes in weight, blood glucose and lipid. The patient's metabolic parameters should be evaluated at the start of treatment and parameters should be controlled regularly during treatment. These parameters should be monitored as a clinical sign.
Venous thrombosis
Cases of venous thrombosis (VTE: Venous Thromboembolism) have been reported to anti -psychotic drugs. Because patients are treated with psychotic drugs, VTE risk factors often appear, all VTE risk factors need to be determined before and during treatment with quetiapine and take preventive measures.
Pancreatitis
pancreatitis is reported in clinical trials and during the use of the drug.
Abuse and addiction
Cases of abuse and drug addiction have been reported. Precautions when prescribing Quetiapin for patients with a history of alcoholism or drug addiction.
Medicine combination
Data on Quetiapin combination with divalproex or lithium treatment of acute impulsive attacks is limited. However, this combination therapy is effective. The effectiveness of treatment appears at the 3rd week.
lactose
Products contain lactose excipients. Patients have rare genetic problems such as galactose intolerance, lactase deficiency or Glucose - Galactose should not use this drug.
The ability to drive and operate machinery
Because Quetiapin can cause drowsiness, patients need to be cautious when driving and operating machinery.
Pregnancy
In the first three months
Based on the results of some individual reports and some observation studies, Quetiapin does not increase the risk of fetal defects. However, the data is limited, so it is not possible to make an accurate conclusion. Therefore, Quetiapin is only for pregnant women when the treatment benefits are higher than the potential risk.
The last three months of pregnancy
Babies are exposed to anti -psychotic drugs (including Quetiapin) during the last three months of pregnancy, which is at risk of unwanted effects on the outskirts of the tower and/or symptoms of cessation after birth. There has been an unwanted effect report, increasing muscle tone, reducing muscle tone, tremor, drowsiness, respiratory failure or eating disorders. Therefore, closely monitoring babies.
Breastfeeding period
So far, information about quetiapin excretion into human milk is limited. Based on the published information, Quetiapin does not excrete on breast milk at the treatment dose. However, due to lack of information, the decision to stop breastfeeding or stop treatment with Quetiapin depends on the importance of the drug for the mother.
Drug interaction
quetiapin mainly acting on the central nervous system, so be careful when coordinating Quetiapin with other medications on other central nervous systems and alcohol.
Be cautious when using quetiapin for patients being treated with acetylcholin anti -acetylcholin (Muscarinic) drugs.
Quetiapin metabolizes mainly thanks to the cytochrom P450 (CYP) enzyme 3A4, the cytochrome p450 enzyme system. In a study in a healthy volunteer, simultaneously used Quetiapin (dose of 25 mg) with ketoconazole, a CYP3A4 inhibitor, increasing 5-8 times the area under the curve of Quetiapin (AUC: Area Under the Curve). On this basis, contraindicated use of Quetiapin with CYP3A4 inhibitors. Grapefruit juice is also not recommended during treatment with Quetiapin.
In a multi -drug test to evaluate the pharmacokinetics of Quetiapin before and during the treatment process with carbamazepin (a liver enzyme induction), the results showed simultaneous use with carbamazepine significantly increasing the liquid of quetiapin. Increasing clearance reduces Quetiapin exposure (measured by AUC) on average 13% compared to the solitary quetiapin, in some cases of this actor greater. This interaction may reduce the plasma concentration of Quetiapin, resulting in a reduction in Quetiapin's treatment effect. Simultaneous use of quetiapin with phenytoin (another enzyme induction drug) increases the clearance of quetiapin about 450%. Patients who are taking liver enzyme drugs, only starting to treat Quetiapin when Quetiapine's treatment benefits are higher than the risk of liver enzyme stopping. The important thing is that any liver enzyme changes should be changed slowly, if necessary, it can be replaced with liver enzyme non -touch drugs (such as sodium valproat).
The pharmacokinetics of Quetiapin does not change significantly when coordinated with imipramine antidepressants (CYP2D6 inhibitors) or fluoxetin (quetiapin inhibitors with phenytoin (another enzyme induction drug) increase the clearance of quetiapin about 450%. Quetiapine is higher than the risk of liver enzyme stopping.The pharmacokinetics of Quetiapin does not change significantly when combined with Risperidon or Haloperidol psychotic drugs. However, combination of quetiapin and thioridazin increases the clearance of Quetiapin about 70%. The pharmacokinetics of Quetiapin does not change when combined with cimetidine. lithium pharmacokinetics do not change when used in combination with quetiapin.In a 6 -week random study, Lithi and Quetiapin release the extended compared to the Placebo and Quetiapin released in adult patients with acute Hung Cam attack, the results showed that the percentage of symptoms of the pagoda, drowsiness and weight gain observed in the Lithi and Quetiapin groups extended higher than the Placeboo group.
Dynamic pharmacokinetics of sodium valproat and quetiapin clinically unchanged when used in combination. A recovery study in children and young people treated with Valproat, Quetiapin or both, research showed a high proportion of neutrophils and neutrophils in the group used to combine compared to the single therapy group.
Quetiapin interaction with cardinal medications used has not been studied.
Be careful when using Quetiapin simultaneously with drugs that cause insomnia of electrolytes and increase QT.
Methadon immune test and three -round antidepressants can give false positive results in patients being treated with Quetiapin.
Cavalry of the drug: Because there is no studies on the corresponding properties of the drug, this drug should not be mixed with other drugs.
Storage
In a dry place, the temperature does not exceed 30 ° C, avoiding light.
Other drugs
- GLYCERYL TRINITRATE TABLETS BP 0.5MG
- NEOMERCAZOLE 5MG TABLETS
- Olanzapine Glenmark
- TEICOPLANIN 400 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION / INFUSION OR ORAL SOLUTION
- Viagra
- Wakix
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions